Renal cell carcinoma--angioinfarction.
In our experience the mortality rate in 46 patients who underwent angioinfarction for renal cell carcinoma was 4 per cent. Fever, ileus and leukocytosis were noted in 86 to 90 per cent of our patients. The use of absolute ethanol as a medium for renal infarction was associated with a significant incidence of damage to other organs. A 30 per cent decrease in tumor volume following angioinfarction using absorbable gelatin sponge and Gianturco coils was noted in 75 per cent of the patients. There was no evidence of metastatic tumor reduction and we could not document any significant decrease in operative time or blood loss. It would appear that there is some increased survival rate in patients with metastasis who are given adjuvant immune ribonucleic acid therapy. However, the numbers in our series are not significant to draw any definite conclusion. It is apparent that patients treated with infarction, delayed nephrectomy and medroxyprogesterone acetate did not have any significant survival over those treated with palliative nephrectomy or chemotherapy. The macrophage maturation assay may be useful during clinical followup.
D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D000792:Angiography; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D000431:Ethanol / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D009367:Neoplasm Staging; D009392:Nephrectomy; D012313:RNA / Q000276:immunology / Q000627:therapeutic use; D012082:Renal Veins / Q000000981:diagnostic imaging; D014684:Venae Cavae / Q000000981:diagnostic imaging
C013674:RNA, immune; D000431:Ethanol; D012313:RNA; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone